CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
M-Trapdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03085238
NCT03085238N/ACompleted
CompareCT.gov

Safety and Performance of Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer

MTrap, Inc.·interventional·Posted Mar 21, 2017·Updated Jan 27, 2020

In Brief

A clinical study evaluating M-Trap for Ovarian Cancer Stage IIIC and Ovarian Cancer Stage IV. Completed, enrolled 23 participants across 8 sites.

Detailed Summary

M-Trap is an implantable medical device designed to capture disseminated tumor cells (DTCs). It is intended for use in advanced-stage ovarian cancer patients. The study objective is to assess the safety and the performance of the M-Trap device.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer Stage IIIC, Ovarian Cancer Stage IV
CountriesSpain
CollaboratorsMedPass International

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 21, 2017
Enrollment StartMar 9, 2017
Primary CompletionSep 12, 2018
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.3 years ago

Interventions

M-Trapdevice

Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).